Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer

Journal of Experimental and Clinical Cancer Research

Volumn 34, Issue 1, 2015, Pages

  Zhang, Zhengxiang ^a   Wang, Min ^b   Zhou, Ling ^b   Feng, Xiao ^a   Cheng, Jin ^a   Yu, Yang ^a   Gong, Yanping ^a   Zhu, Ying ^b   Li, Chuanyuan ^c   Tian, Ling ^a   Huang, Qian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^c DUKE UNIVERSITY   (United States)

Author keywords

Caspase 3; Colorectal cancer; Dying cells; High mobility group box 1(HMGB1); Tumor cell proliferation

Indexed keywords

CASPASE 3; CLEAVED CASPASE 3; CYCLINE; HIGH MOBILITY GROUP B1 PROTEIN; KI 67 ANTIGEN; UNCLASSIFIED DRUG; ACYLTRANSFERASE; ADVANCED GLYCATION END PRODUCT RECEPTOR; HTATIP2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FOLLOW UP; HT 29 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADICAL RESECTION; SEX DIFFERENCE; TELEPHONE INTERVIEW; TUMOR GROWTH; WESTERN BLOTTING; COLORECTAL TUMOR; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROTEIN DEGRADATION; TUMOR CELL LINE; VERY ELDERLY;

ACETYLTRANSFERASES; ADULT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; HMGB1 PROTEIN; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROTEOLYSIS; TRANSCRIPTION FACTORS;

EID: 84930211731     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-015-0166-1     Document Type: Article

References (28)

1. Niero EL, Rocha-Sales B, Lauand C, Cortez BA, de Souza MM, Rezende-Teixeira P, et al. The multiple facets of drug resistance: one history, different approaches. J Exp Clin Cancer Res. 2014;33:37. doi:10.1186/1756-9966-33-37.
2. Cheng J, Tian L, Ma J, Gong Y, Zhang Z, Chen Z, et al. Dying tumor cells stimulate proliferation of living tumor cells via caspase-dependent protein kinase Cdelta activation in pancreatic ductal adenocarcinoma. Mol Oncol. 2015;9(1):105-14. doi:10.1016/j.molonc.2014.07.024.
3. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med. 2011;17(7):860-6. doi:10.1038/nm.2385.
4. Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015;517(7533):209-13. doi:10.1038/nature14034.
5. Ford CA, Petrova S, Pound JD, Voss JJ, Melville L, Paterson M, et al. Oncogenic properties of apoptotic tumor cells in aggressive B cell lymphoma. Curr Biol. 2015;25(5):577-88. doi:10.1016/j.cub.2014.12.059.
6. Kono K, Mimura K, Kiessling R. Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis. 2013;4:e688. doi:10.1038/cddis.2013.207.
7. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev. 2006;17(3):189-201. doi:10.1016/j.cytogfr.2006.01.003.
8. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367-88. doi:10.1146/annurev.immunol.021908.132603.
9. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem. 1995;270(43):25752-61.
10. Sorci G, Riuzzi F, Giambanco I, Donato R. RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta. 2013;1833(1):101-9. doi:10.1016/j.bbamcr.2012.10.021.
11. Liu W, Zhang Z, Zhang Y, Chen X, Guo S, Lei Y, et al. HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway. Cancer Biol Ther. 2015:0. doi:10.1080/15384047.2015.1017691.
12. Pan B, Chen D, Huang J, Wang R, Feng B, Song H, et al. HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma. Mol Cancer. 2014;13:165. doi:10.1186/1476-4598-13-165.
13. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol. 2002;196(2):163-70. doi:10.1002/path.1031.
14. Sasahira T, Akama Y, Fujii K, Kuniyasu H. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch. 2005;446(4):411-5. doi:10.1007/s00428-005-1210-x.
15. Hongo K, Kazama S, Tsuno NH, Ishihara S, Sunami E, Kitayama J, et al. Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study. World J Surg Oncol. 2015;13(1):7. doi:10.1186/1477-7819-13-7.
16. Mahmood T, Yang PC. Western blot: technique, theory, and trouble shooting. N Am J Med Sci. 2012;4(9):429-34. doi:10.4103/1947-2714.100998.
17. Rasband WS. ImageJ. National Institutes of Health, Bethesda, Maryland, USA. http://imagej.nih.gov/ij; 1997-2014.
18. Sawai H, Domae N. Discrimination between primary necrosis and apoptosis by necrostatin-1 in Annexin V-positive/propidium iodide-negative cells. Biochem Biophys Res Commun. 2011;411(3):569-73. doi:10.1016/j.bbrc.2011.06.186.
19. Challa S, Chan FK. Going up in flames: necrotic cell injury and inflammatory diseases. Cell Mol Life Sci. 2010;67(19):3241-53. doi:10.1007/s00018-010-0413-8.
20. Compton C, Byrd D, Garcia-Aguilar J, Kurtzman S, Olawaiye A, Washington M. Colon and rectum. In: Compton CC, Byrd DR, Garcia-Aguilar J, Kurtzman SH, Olawaiye A, Washington MK, editors. AJCC cancer staging atlas. New York: Springer; 2012. p. 185-201.
21. Lin L, Zhong K, Sun Z, Wu G, Ding G. Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol. 2012;138(1):11-22. doi:10.1007/s00432-011-1067-0.
22. Shepherd NA, Richman PI, England J. Ki-67 derived proliferative activity in colorectal adenocarcinoma with prognostic correlations. J Pathol. 1988;155(3):213-9. doi:10.1002/path.1711550306.
23. Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 2003;21(2):241-50. doi:10.1200/jco.2003.05.044.
24. Huebener P, Pradere JP, Hernandez C, Gwak GY, Caviglia JM, Mu X, et al. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest. 2015;125(2):539-50. doi:10.1172/JCI76887.
25. Thorburn J, Horita H, Redzic J, Hansen K, Frankel AE, Thorburn A. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ. 2008;16(1):175-83. doi:10.1038/cdd.2008.143.
26. Stoimenov I, Helleday T. PCNA on the crossroad of cancer. Biochem Soc Trans. 2009;37(Pt 3):605-13. doi:10.1042/BST0370605.
27. Kang R, Zhang Q, Zeh 3rd HJ, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? Clin Cancer Res. 2013;19(15):4046-57. doi:10.1158/1078-0432.CCR-13-0495.
28. Wu X, Liu W, Cao Q, Che C, Chen Z, Xu Z, et al. Inhibition of Aurora B by CCT137690 sensitizes colorectal cells to radiotherapy. J Exp Clin Cancer Res. 2014;33:13. doi:10.1186/1756-9966-33-13.